AG-120 (ivosidenib), a first in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma

被引：3
|
作者：
Ishii, Yuko [1 ]
Sigel, Carlie [2 ]
Lowery, Maeve A. [2 ]
Goyal, Lipika [3 ]
Gliser, Camelia [1 ]
Jiang, Liewen [1 ]
Pandya, Susan [1 ]
Bin Wu [1 ]
Choe, Sung [1 ]
Deshpande, Vikram [3 ]
机构：
[1] Agios Pharmaceut Inc, Cambridge, MA USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A071
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
    Lowery, Maeve Aine
    Abou-Alfa, Ghassan K.
    Burris, Howard A.
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer Saba
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Ishii, Yuko
    Auer, Julia
    Gliser, Camelia
    Agresta, Samuel V.
    Pandya, Shuchi Sumant
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Clinical and radiological response of Maffucci related enchondromas to mutant IDH1 inhibitor Ivosidenib
    Funck-Brentano, Thomas
    Cohen-Solal, Martine
    Ducray, Francois
    Mandonnet, Emmanuel
    BONE, 2024, 188
  • [23] Evaluation of drug-drug interaction of itraconazole and ivosidenib (AG-120), an oral, potent, targeted, small molecule inhibitor of mutant IDH1, in healthy subjects
    Fan, B.
    Prakash, C.
    Liu, H.
    Liu, G.
    Korth, C.
    Yang, H.
    Dai, D.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E40 - E41
  • [24] Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.
    Pollyea, Daniel Aaron
    Dinardo, Courtney Denton
    de Botton, Stephane
    Stein, Eytan
    Roboz, Gail J.
    Mims, Alice S.
    Swords, Ronan T.
    Altman, Jessica K.
    Collins, Robert
    Mannis, Gabriel N.
    Uy, Geoffrey L.
    Donnellan, William Bruce
    Pigneux, Arnaud
    Fathi, Amir Tahmasb
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, C.
    Stein, A.
    Stein, E.
    Fathi, A.
    Frankfurt, O.
    Schuh, A.
    Doehner, H.
    Martinelli, G.
    Patel, P.
    Raffoux, E.
    Tan, P.
    Zeidan, A.
    de Botton, S.
    Kantarjian, H.
    Stone, R.
    Lam, D.
    Wang, X.
    Gong, J.
    Kapsalis, S.
    Hickman, D.
    Zhang, V.
    Winkler, T.
    Wu, B.
    Vyas, P.
    ANNALS OF HEMATOLOGY, 2019, 98 : S40 - S41
  • [26] An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
    Rohle, Dan
    Popovici-Muller, Janeta
    Palaskas, Nicolaos
    Turcan, Sevin
    Grommes, Christian
    Campos, Carl
    Tsoi, Jennifer
    Clark, Owen
    Oldrini, Barbara
    Komisopoulou, Evangelia
    Kunii, Kaiko
    Pedraza, Alicia
    Schalm, Stefanie
    Silverman, Lee
    Miller, Alexandra
    Wang, Fang
    Yang, Hua
    Chen, Yue
    Kernytsky, Andrew
    Rosenblum, Marc K.
    Liu, Wei
    Biller, Scott A.
    Su, Shinsan M.
    Brennan, Cameron W.
    Chan, Timothy A.
    Graeber, Thomas G.
    Yen, Katharine E.
    Mellinghoff, Ingo K.
    SCIENCE, 2013, 340 (6132) : 626 - 630
  • [27] Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies
    Le, Kha
    Wada, Russ
    Dai, David
    Fan, Bin
    Liu, Guowen
    Liu, Hua
    Attar, Eyal C.
    Agresta, Samuel V.
    Yang, Hua
    BLOOD, 2018, 132
  • [28] High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
    Daigle, Scott R.
    Choe, Sung
    Quek, Lynn
    DiNardo, Courtney D.
    Stein, Anthony
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Kantarjian, Hagop M.
    Zhang, Vickie
    Winkler, Thomas
    Vyas, Paresh
    Wu, Bin
    BLOOD, 2019, 134
  • [29] Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
    Chandhok, Namrata S.
    Wei, Wei
    Halene, Stephanie
    Prebet, Thomas
    BLOOD, 2019, 134
  • [30] REAL-WORLD ASSESSMENT OF IDH1 INHIBITOR IVOSIDENIB IN IDH MUTANT LOWER GRADE GLIOMAS - THE JOHNS HOPKINS EXPERIENCE
    Puri, Sushant
    Shi, Jessica
    Blair, Lindsay
    Blakeley, Jaishri
    Laterra, John
    Kamson, David
    NEURO-ONCOLOGY, 2022, 24 : 181 - 181
12345